Major Events - Meili Tianyuan Medical Health (02373) acquires 100% of Shanghai Siyuanli Industrial for 1.25 billion yuan, aiming to capture the high-end beauty market in major cities [1] - Jinhai Medical Technology (02225) is actively preparing to participate in the 8th China International Import Expo [1] - China Biopharmaceutical (01177) has its selective MEK1/2 inhibitor TQ-B3234 included in the breakthrough therapy designation program [1] - Beijing Jiakesi plans to sell 90% of Jiakexi Health through capital increase and equity transfer agreements [1] - Green Power Environmental (01330) intends to invest in establishing a joint venture in Hong Kong to expand overseas environmental business [1] - Zhonghui Biotechnology (02627) applies for full circulation of H-shares [1] Operating Performance - Legend Holdings (03396) reports that its subsidiary, Legend New Science (003022.SZ), achieved a net profit attributable to shareholders of 232 million yuan in the first three quarters, an increase of 30.32% [1] - Mongol Mining (00975) reports total raw coal production of 3.6043 million tons from UHG and BN mines in the third quarter [1] - China Resources Power (00836) reports cumulative electricity sales of 161 million megawatt-hours from its subsidiary power plants in the first nine months, a year-on-year increase of 4.2% [1] - China Coal Energy (01898) reports coal sales of 19.66 million tons in September, a year-on-year decrease of 20.1% [1] - Air China (00753) reports a 1.2% year-on-year increase in passenger capacity input and a 5.6% year-on-year increase in passenger turnover in September [1]

Investment Rating - The report assigns a positive outlook on Beauty Farm Medical and Health Industry, indicating a strong potential for growth following the acquisition of Siyanli [1][5]. Core Insights - The acquisition of Siyanli for RMB 1.25 billion is a strategic move to enhance Beauty Farm's market position in the premium beauty sector, consolidating its leadership alongside Narui'er and Siyanli [1][10]. - The transaction structure includes a mix of cash, acquisition loans, and share issuance, ensuring financial stability and effective integration of Siyanli's operations [2][9]. - The merger is expected to significantly increase the number of stores in key urban areas, enhancing market share and operational synergies [3][10]. - The integration of Siyanli's customer base and resources is projected to boost overall membership and revenue potential, particularly in high-end commercial properties [4][11]. - Siyanli's valuation is attractive, with a lower P/E ratio compared to Beauty Farm and the industry average, providing a margin of safety for investors [5][12]. Summary by Sections Acquisition Details - Beauty Farm announced the acquisition of 100% equity in Siyanli for RMB 1.25 billion, marking a key step in its growth strategy [1][8]. - The acquisition is financed through a combination of internal cash, bank loans, and share issuance, with a total cash consideration of approximately RMB 840 million [2][9]. Market Position - The acquisition will increase Beauty Farm's store network from 552 to 734, solidifying its position as a leader in China's high-end beauty services market [3][10]. - The top 20 core cities contribute about 40% of the beauty services market, with significant revenue generated from first-tier cities [3][10]. Integration and Synergies - The merger is expected to enhance competitive advantages by integrating three leading brands and increasing coverage in high-end commercial properties [4][11]. - The addition of Siyanli's 60,000 members will increase the overall member base by 44%, facilitating cross-selling opportunities [4][11]. Financial Impact - Siyanli's valuation at 14.8x LTM P/E is significantly lower than Beauty Farm's 29.5x, indicating a favorable investment opportunity [5][12]. - The acquisition is anticipated to replicate the successful integration of Narui'er, with potential for improved operational efficiency and profitability [5][14].

Core Viewpoint - Meili Tianyuan Medical Health (02373) repurchased 50,000 shares on October 15, 2025, for a total transaction amount of approximately HKD 1.69481 million, with an average price of about HKD 33.90 per share [1] Summary by Category - **Share Repurchase Details** - The company repurchased 50,000 shares [1] - Total transaction amount was approximately HKD 1.69481 million [1] - The average price per share was about HKD 33.90 [1]

智通财经APP讯，美丽田园医疗健康(02373)公布，公司于2025年10月15日于市场购回5万股公司股份， 总交易金额约169.481万港元，交易平均价约每股33.90港元。 ...

Core Viewpoint - Meili Tianyuan Medical Health (02373.HK) announced a share buyback of 50,000 shares on October 15, 2025, for a total transaction amount of approximately HKD 1.6948 million, with an average price of about HKD 33.90 per share [1] Group 1 - The current share price does not reflect the intrinsic value of the shares and the actual business prospects of the company [1] - The board believes that the share buyback demonstrates management's strong confidence in the long-term value of the enterprise [1] - The buyback is expected to enhance the group's market value and shareholder return capabilities [1] Group 2 - The share buyback aligns with the overall interests of the company and its shareholders [1]

表格類別： 股票 狀態： 新提交 公司名稱： 美麗田園醫療健康產業有限公司 呈交日期： 2025年10月15日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02373 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/ ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Beauty Farm Medical and Health Industry Inc. 美麗田園醫療健康產業有限公司 * （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：2373） 自願公告 市場股份回購 本公告由美麗田園醫療健康產業有限公司（「本公司」，連同其附屬公司統稱「本集 團」）自願刊發。 本公司欣然公佈，本公司於2025年10月15日於市場購回50,000股本公司股份，總交 易金額約1,694,810港元，交易平均價約每股33.90港元。 本公司董事（「董事」）會（「董事會」）認為，目前的股份成交價並不反映股份的內在價 值和本公司的實際業務前景。董事會相信，股份購回體現了管理層對企業長期價值 的堅定信心，有利於提升本集團資本市場價值及股東回報能力。本次股份購回符合 本公司及其股東的整體利益。 董事會本次回購是通過於2025年6月27日舉行的本公司股東週年大會（「 ...

每经AI快讯，美丽田园医疗健康(02373.HK)早盘涨近5%，截至发稿，涨4.7%，报37.42港元，成交额 1172.89万港元。 （文章来源：每日经济新闻） ...

Core Viewpoint - Meili Tianyuan Medical Health (02373) is set to acquire 100% of Shanghai Siyuanli Industrial for 1.25 billion yuan (approximately 1.369 billion HKD), which is expected to enhance its market position and expand its store network significantly [1] Group 1: Acquisition Details - The acquisition of Shanghai Siyuanli Industrial will allow Meili Tianyuan to own the high-end skincare brand "Siyuanli" in China [1] - Post-acquisition, the number of stores is projected to reach 734, indicating rapid expansion [1] Group 2: Market Position and Growth Potential - Meili Tianyuan is recognized as a leading player in the domestic beauty and medical beauty service sector, with a strong brand reputation and operational capabilities [1] - The company is expected to see performance growth driven by deepening digital transformation, improved supply chain layout, and ongoing store expansion [1] Group 3: Analyst Insights - Huachuang Securities has issued a report projecting a compound annual growth rate for profits over the next three years, alongside a target price of 43.56 HKD, maintaining a "strong buy" rating [1]

Core Viewpoint - Meili Tianyuan Medical Health (02373) is set to acquire 100% of Shanghai Siyuanli Industrial for 1.25 billion yuan (approximately 1.369 billion HKD), which is expected to significantly expand its store network and strengthen its market position in the high-end skincare sector [1]. Company Summary - Meili Tianyuan Medical Health's stock rose nearly 5% in early trading, reaching 37.42 HKD with a trading volume of 11.7289 million HKD [1]. - The acquisition of Shanghai Siyuanli, which owns the high-end skincare brand "Siyuanli," is anticipated to increase the number of stores to 734 [1]. - The company aims to leverage its "Double Beauty + Double Healthcare" business model to enhance its industry position and market share [1]. Industry Summary - Huachuang Securities has noted that Meili Tianyuan is a leading player in the domestic beauty and medical beauty service sector, with a strong brand reputation and operational capabilities [1]. - The company is expected to see growth in performance due to deepening digital transformation, improved supply chain layout, and ongoing store expansion [1]. - The target price for Meili Tianyuan is set at 43.56 HKD, maintaining a "strong buy" rating based on projected profit compound growth over the next three years and comparable company valuations [1].